coronary artery disease (CAD)
Conditions
Interventions
Group R:Induction of anesthesia: 0.2mg /kg remimazolam tosilate + 1.0µg /kg sufentanil, BIS=70, intravenous injection of rocuronium 0.6-1.0mg /kg. 5 minutes after induction, if BIS=60, endotracheal in
If BIS is still > 60, add remimazolam 0.05 mg/kg per time, evaluate BIS again 2 minutes later, and add more if necessary. Anesthesia maintenance: remimazolam 0.2-2.0 mg/kg/h, Sufentanil 0.6 µg/kg/h,
Group E:Induction of anesthesia: 0.3mg /kg etomidate + 1.0µg /kg sufentanil, BIS=70, intravenous injection of rocuronium 0.6-1.0mg /kg. 5 minutes after induction, if BIS=60, endotracheal intubation wi
If BIS is still > 60, add etomidate 0.05 mg/kg per time, evaluate BIS again 2 minutes later, and add more if necessary. Anesthesia maintenance: propofol 4-10 mg/kg/h, Sufentanil 0.6 µg/kg/h, rocuroni
Sponsors
Zibo Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients undergoing scheduled off-pump coronary artery bypass grafting; 2. Aged 18-75 years old; 3. American Society of Anesthesiologists physical status ?-?; 4. Body Mass Index 18-30kg/m2; 5. Written informed consent form received from the patient or patient's legal representative.
Exclusion criteria
Exclusion criteria: 1. Severe arrhythmia, including severe sinus bradycardia (heart rate=50 beats per minutes), atrial fibrillation, third-degree atrioventricular block, frequent atrial premature beats, frequent ventricular premature beats. 2. Uncontrolled or poorly controlled hypertension (SBP=180mmHg and/or DBP=110 mmHg). 3. Abnormal liver or kidney dysfunction (Child-Pugh class B or C, BUN exceed 1.5 times of the upper limit of medical reference value and/or creatinine exceeds the upper limit of medical reference value. 4. Adrenal cortical dysfunction (serum cortisol <3µg/dL); 5. Allergy to the investigational drugs, such as remimazolam tosilate, etomidate, rocuronium. 6. Taking sedatives, hypnotics, antidepressants. 7. History of drug abuse, alcoholism; 8. Myasthenia gravis; 9. Patients with schizophrenia, severe depression, cognitive impairment, inability to communicate. 10. Other patients deemed unsuitable for inclusion by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| fluctuation of mean artery pressure during induction period, ?MAP; | — |
Secondary
| Measure | Time frame |
|---|---|
| AEs (hypotension, hypertension, tachycardia, bradycardia);Total dosage of vasoactive drugs in anesthesia induction and maintenance; | — |
Countries
China
Contacts
Public ContactJiguo Si
Zibo Central Hospital
Outcome results
None listed